Amyloid-β Clearance Mechanisms in Alzheimer's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Amyloid-β Clearance Mechanisms in Alzheimer's Disease — Stella

Home/Alzheimer's Disease (AD)/

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer's Disease (AD) trials

Trial locations(1 site)

Germany

Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums, München, Bavaria

Key details

Sponsor

Ludwig-Maximilians - University of Munich

Enrollment target

~60 participants

Started

June 2021

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

50 Years – 85 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.